Please login to the form below

Not currently logged in

Bayer enters agreement with Celera

Bayer Schering Pharma AG, Germany, has entered into an exclusive licence agreement with US biotech company Celera Corporation

Bayer Schering Pharma AG, Germany, has entered into an exclusive licence agreement with US biotech company Celera Corporation. Bayer will pay Celera a one-off fee for exclusive access to five cancer target molecules and additional payments for particular development and commercial milestones. Celera will also receive royalties based on net sales of commercialised products.

"We look forward to exploring the full potential of these promising target candidates with regard to therapeutic interference for anti-tumour therapy as well as in in-vivo diagnostic imaging", said Professor Khusru Asadullah head of target discovery at Bayer Schering Pharma. 

Celera Genomics was founded in 1988 with the aim of sequencing and assembling the human genome. It was acquired by Applera Corporation but separated from that company and started trading on Nasdaq in July 2008. It recently moved its base from Maryland Washington, to Alameda, California and is now focused on developing personalised diagnostics and medicines. Steve Ruben, vice president of proteomic research at the company, said: "This agreement combines the strength of our novel proteomics target discovery platform with Bayer Schering Pharma's expertise in research and development." 

30th June 2009


Featured jobs

Subscribe to our email news alerts


Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...